Integer Holdings Corporation Faces Class Action for Securities Fraud, Investors Can Claim Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: Globenewswire
- Legal Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Integer Holdings Corporation for violations of securities laws, covering transactions from July 25, 2024, to October 22, 2025, with a deadline for participation set for February 9, 2026.
- False Statement Allegations: The complaint alleges that Integer exaggerated its competitive position in the electrophysiology market, leading to weakened sales of various EP devices, with public statements deemed false and misleading, impacting investor decisions.
- Market Reaction: As the market learned the truth about Integer, investors suffered losses, indicating that the company's false claims regarding long-term growth drivers in the cardiovascular segment negatively affected its stock price.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to join the lawsuit to seek compensation, highlighting the importance of protecting investor rights.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 82.790
Low
69.00
Averages
91.75
High
140.00
Current: 82.790
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
